Clinical Trial Details
| Trial ID: | L6460 |
| Source ID: | NCT03910361 |
| Associated Drug: | Evogliptin |
| Title: | Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type2 Diabetes|Non-Alcoholic Fatty Liver Disease |
| Interventions: | DRUG: Evogliptin|DRUG: Pioglitazone |
| Outcome Measures: | Primary: Changes from baseline intrahepatic fat (%), Changes from baseline intrahepatic fat (%) after treatment with evogliptin or pioglitazone, 24 weeks | |
| Sponsor/Collaborators: | Sponsor: Dong-A ST Co., Ltd. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 51 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2019-04-12 |
| Completion Date: | 2020-07-02 |
| Results First Posted: | |
| Last Update Posted: | 2021-04-29 |
| Locations: | Samsung Medical Center, Changwon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Keimyung Dongsan University Medical Center, Daegu, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Korea, Republic of|Catholic University of Seoul ST.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT03910361 |
